FinscoFinsco

Perspective Therapeutics (US.CATX)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CATX · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion121.8%→
ROE-7.5%↓
Cash Conversion-→
D/E Ratio0.01↑
Gross Margin-→
US.CATX (Perspective Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   121.8%    →
ROE               -7.5%    ↓
Cash Conversion       -    →
D/E Ratio          0.01    ↑
Gross Margin          -    →
Key Metrics
US.CATX (Perspective Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 121.8% →
ROE -7.5% ↓
Cash Conversion - →
D/E Ratio 0.01 ↑
Gross Margin - →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies